PL362172A1 - Kompozycja farmaceutyczna o polepszonej wchłanialności - Google Patents

Kompozycja farmaceutyczna o polepszonej wchłanialności

Info

Publication number
PL362172A1
PL362172A1 PL01362172A PL36217201A PL362172A1 PL 362172 A1 PL362172 A1 PL 362172A1 PL 01362172 A PL01362172 A PL 01362172A PL 36217201 A PL36217201 A PL 36217201A PL 362172 A1 PL362172 A1 PL 362172A1
Authority
PL
Poland
Prior art keywords
medicinal compositions
improved absorbability
absorbability
improved
medicinal
Prior art date
Application number
PL01362172A
Other languages
English (en)
Inventor
Eiji Nara
Original Assignee
Takeda Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.
Publication of PL362172A1 publication Critical patent/PL362172A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL01362172A 2000-12-11 2001-12-11 Kompozycja farmaceutyczna o polepszonej wchłanialności PL362172A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000375608 2000-12-11
PCT/JP2001/010827 WO2002048142A1 (en) 2000-12-11 2001-12-11 Medicinal compositions having improved absorbability

Publications (1)

Publication Number Publication Date
PL362172A1 true PL362172A1 (pl) 2004-10-18

Family

ID=18844596

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01362172A PL362172A1 (pl) 2000-12-11 2001-12-11 Kompozycja farmaceutyczna o polepszonej wchłanialności

Country Status (10)

Country Link
US (1) US20040053972A1 (pl)
EP (1) EP1350793A1 (pl)
KR (1) KR20040025881A (pl)
CN (1) CN1487936A (pl)
AU (1) AU2002221115A1 (pl)
CA (1) CA2431322A1 (pl)
HU (1) HUP0400683A2 (pl)
NO (1) NO20032614L (pl)
PL (1) PL362172A1 (pl)
WO (1) WO2002048142A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1439178A4 (en) * 2001-10-05 2005-11-16 Takeda Pharmaceutical Heterocyclic compounds, oxazole derivatives, process for their preparation and their use
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
BRPI0414532B1 (pt) * 2003-09-19 2018-06-05 Astrazeneca Ab Composto derivado de quinazolina, processo para preparar 0 mesmo, composição farmaceutica, e, uso de um composto derivado de quinazolina
ES2379631T3 (es) * 2003-10-08 2012-04-30 Meiji Seika Pharma Co., Ltd. Composición antibacteriana no cristalina que contiene cefditoren pivoxilo
US7259262B2 (en) * 2003-10-24 2007-08-21 Hoffmann-La Roche Inc. Arylazole derivatives, their manufacture and use as pharmaceutical agents
JP4639745B2 (ja) * 2004-01-19 2011-02-23 青葉化成株式会社 難固結性のタンパク質変性抑制剤粉末およびその使用方法
US20080138437A1 (en) * 2004-02-09 2008-06-12 Shuji Sakuma Antitumor Agent
EP1814544A4 (en) * 2004-11-05 2009-12-02 Cephalon Inc CANCER TREATMENTS
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
WO2006087919A1 (ja) * 2005-01-28 2006-08-24 Takeda Pharmaceutical Company Limited 難水溶性物質含有微細化組成物
EP1872798B1 (en) * 2005-04-06 2013-06-05 Kabushiki Kaisha Sangi Intestinal absorptive anti-tumor agent
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
MX2010012442A (es) * 2008-05-13 2011-10-11 Astrazeneca Ab Sal de fumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-m etilcarbamoilmetil) piperidin-4-il]oxi}quinazolina.
US7749300B2 (en) * 2008-06-05 2010-07-06 Xerox Corporation Photochemical synthesis of bimetallic core-shell nanoparticles
CN104224703A (zh) * 2008-09-25 2014-12-24 赛福伦公司 苯达莫司汀的液体配制品
KR20110110293A (ko) * 2009-01-15 2011-10-06 세파론, 인코포레이티드 벤다무스틴 유리 염기의 신규 형태
KR102000312B1 (ko) * 2011-10-14 2019-07-15 어레이 바이오파마 인크. Erb2 (her2) 저해제의 고체 분산물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU4314196A (en) * 1994-12-21 1996-07-10 Yamanouchi Pharmaceutical Co., Ltd. Solid composition with improved solubility and absorbability
AU3461697A (en) * 1996-07-19 1998-02-10 Takeda Chemical Industries Ltd. Heterocyclic compounds, their production and use

Also Published As

Publication number Publication date
NO20032614L (no) 2003-08-05
CN1487936A (zh) 2004-04-07
WO2002048142A1 (en) 2002-06-20
HUP0400683A2 (hu) 2004-06-28
AU2002221115A1 (en) 2002-06-24
CA2431322A1 (en) 2002-06-20
EP1350793A1 (en) 2003-10-08
US20040053972A1 (en) 2004-03-18
KR20040025881A (ko) 2004-03-26
NO20032614D0 (no) 2003-06-10

Similar Documents

Publication Publication Date Title
GB2358583B (en) Pharmaceutical compositions
IL152659A0 (en) Pharmaceutical composition
EG24357A (en) New Pharmaceutical composition
HUP0300582A3 (en) Pharmaceutical compositions
SI1524266T1 (sl) Farmacevtski sestavek
AU6219601A (en) Pharmaceutical compositions
HUP0204555A3 (en) Pharmaceutical composition
GB0009584D0 (en) Pharmaceutical compositions
AU8576801A (en) Pharmaceutical compositions
GB0025473D0 (en) Pharmaceutical combinations
HUP0400553A3 (en) Pharmaceutical compositions
AU2002221115A1 (en) Medicinal compositions having improved absorbability
IL154238A0 (en) Pharmaceutical composition
GB0008485D0 (en) Pharmaceutical compositions
GB0009613D0 (en) Pharmaceutical compositions
GB0009609D0 (en) Therapeutic compositions
GB0030857D0 (en) Therapeutic compositions
GB0005382D0 (en) Pharmaceutical composition
AU8254101A (en) Medicinal compositions
GB0101094D0 (en) Pharmaceutical composition
GB0002691D0 (en) Pharmaceutical composition
GB0019599D0 (en) Pharmaceutical composition
GB0006301D0 (en) Pharmaceutical composition
GB0016684D0 (en) Pharmaceutical composition
GB0027375D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)